Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tamoxifen citrate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Tamoxifen citrate. Displaying page 1 of 1.
    EudraCT Number: 2005-001698-89 Sponsor Protocol Number: Monet Start Date*: 2006-06-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen
    Medical condition: Early or locally advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010059-28 Sponsor Protocol Number: 1110 Start Date*: 2009-06-03
    Sponsor Name:VVOG
    Full Title: Addition to main protocol Leiden CYPTAM for Belgian centres only Protocol outline – CYP-TAMBRUT-3 Prevalence of genetic polymorphisms in genes coding for tamoxifen metabolising enzymes, in postme...
    Medical condition: postmenopausal women with an early ER-positive breast cancer and not previously treated with an endocrine agent or hormone replacement therapy , with an intact uterus and clearly measurable thin en...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004536-28 Sponsor Protocol Number: 1 Start Date*: 2021-11-15
    Sponsor Name:Uppsala University, Department of Women's and Children´s Health
    Full Title: Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longi...
    Medical condition: Most troublesome vulvovaginal atrophy symptom
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004554-42 Sponsor Protocol Number: TAMDMD Start Date*: Information not available in EudraCT
    Sponsor Name:University of Basel Children's Hospital, Division of Neuropediatrics
    Full Title: Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001931-36 Sponsor Protocol Number: CLEE011E2301 Start Date*: 2014-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the t...
    Medical condition: premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) BE (Completed) IT (Completed) PT (Completed) PL (Completed) BG (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000398-10 Sponsor Protocol Number: EFC16133 Start Date*: 2022-04-19
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A randomized, multicenter, double-blind, Phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone receptor-positive, human epidermal growth factor 2-neg...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) EE (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001521-41 Sponsor Protocol Number: UoL001304 Start Date*: 2017-09-18
    Sponsor Name:University of Liverpool
    Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer
    Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-000168-28 Sponsor Protocol Number: IBCSG25-02/BIG3-02 Start Date*: 2005-11-21
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
    Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004332-79 Sponsor Protocol Number: GINECO-BR105 Start Date*: 2007-07-10
    Sponsor Name:ARCAGY
    Full Title: "Essai multicentrique de phase II randomisé évaluant la tolérance et l'efficacité du tamoxifène seul versus association Tamoxifène-RAD001 (Everolimus), chez les patientes atteintes de cancer du sei...
    Medical condition: metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000166-13 Sponsor Protocol Number: 24-02 Start Date*: 2005-05-12
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.
    Medical condition: Histologically proven, resected breast cancer with ER and/or PgR positive tumors
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended) SE (Completed) DE (Completed) ES (Completed) IE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-001036-22 Sponsor Protocol Number: SOLTI-1114 Start Date*: 2013-10-15
    Sponsor Name:SOLTI
    Full Title: PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer
    Medical condition: Untreated invasive breast carcinoma eligible for primary definitive surgery (Stage I-IIIA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002625-31 Sponsor Protocol Number: 10041 Start Date*: 2006-12-11
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Microarray In Node negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy. A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathologi...
    Medical condition: Lymph-node negative early breast cancer and breast cancer with 1 to 3 positive nodes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) ES (Completed) SI (Completed) DE (Completed) GB (Completed) IT (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004548-30 Sponsor Protocol Number: D7917C00225 (1839IL/0225) Start Date*: 2005-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II randomised, double-blind, stratified, multi-centre trial comparing the Nolvadex 20 mg and placebo combination to the Nolvadex 20 mg and ZD1839 (IRESSA™) 250 mg combination in patients wi...
    Medical condition: Female patients aged ³18 years, pre/post menopausal with ER and/or PR positive metastatic adenocarcinoma of the breast determined by each laboratory in each centre. Patients will be stratified int...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002626-59 Sponsor Protocol Number: 26-02/BIG 4-02 Start Date*: 2005-11-21
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy
    Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors for whom there is an uncertain role for adding chemotherapy to the adjuvant treatment program
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005453-38 Sponsor Protocol Number: SuccessC-Trial Start Date*: 2008-12-17
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies SUCCESS C-Trial
    Medical condition: Patients with primary epithelial invasive carcinoma of the breast pT1-4, pN0-3, pM0
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005184-42 Sponsor Protocol Number: CLEE011A2412B Start Date*: 2022-04-15
    Sponsor Name:NOVARTIS PHARMA AG
    Full Title: A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study
    Medical condition: HR+, HER2- advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003620-32 Sponsor Protocol Number: MNEMOSYNE-0712 Start Date*: 2008-11-20
    Sponsor Name:Centre Oscar Lambret
    Full Title: Etude Prospective Randomisée Ouverte et Multicentrique évaluant les effets sur les fonctions cognitives de l’hormonothérapie adjuvante dans le cancer du sein de la femme ménopausée
    Medical condition: Cancer du sein non métastatique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002676-27 Sponsor Protocol Number: MedOPP096-MO39229 Start Date*: 2017-05-25
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study
    Medical condition: HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001462-17 Sponsor Protocol Number: WSG-AM06 Start Date*: 2012-03-29
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
    Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005341-44 Sponsor Protocol Number: ICT Start Date*: 2015-05-04
    Sponsor Name:Medical University of Graz
    Full Title: Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma
    Medical condition: Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 15:46:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA